Genentech Wins Growth Hormone Patent Suit

South San Francisco, Calif. -- August 5, 1988 -- The Federal District Court in San Francisco, California has decided as a matter of law that claims of a suit filed in September 1986 against Genentech, Inc. by the Hormone Research Foundation and its licensee, Hoffman La Roche, Inc. are invalid.

The Court granted a summary judgment that Genentech does not infringe U.S. Patent 3,858,833 by its manufacture and sale of recombinant human growth hormone. Genentech markets Protropin® human growth hormone for the treatment of children with growth hormone deficiency. 1987 sales of Protropin exceeded $86 million.

Genentech is a leading biotechnology company focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.

# # #